Decreased oscillatory flow decreases <i>klf2a</i> expression. by Julien Vermot (257990)

“…(L) Quantitative RT-PCR showing the expression level of several flow-responsive genes after lidocaine treatment. <i>klf2a</i> expression is significantly decreased after 6 and 10 h of treatment and is restored by incubation at 34°C; 100% of expression corresponds to a normal expression level. …”

Proteasome activity was decreased in the <i>myc-rpt6-S119A</i> mutant. by Esther Magdalena Marquez-Lona (4183126)

“…The mean ± SEM rate of Suc-LLVY-AMC cleavage is decreased in the <i>myc-rpt6-S119A</i> mutant compared to the WT and <i>myc-rpt6-S119D</i> strains. …”

Effectiveness of interventions to decrease hesitancy. by Maximilian Nicolaus Burger (12969212)

PowerPoint Slides for: Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis by Bushinsky D.A. (3246690)

“…<b><i>Conclusions:</i></b> In 6 hyperkalemic HD patients, patiromer decreased serum K and P levels and increased fecal K.…”

Sphere-forming efficiency decreases following radiation. by Vicky T. Nguyen (5029244)

<i>Kdm6a</i> conditional KO mice have decreased repopulating potential in serial competitive transplantation assays. by Ling Tian (107492)

“…Whole BM cells were harvested from all cohorts of young <i>Kdm6a</i> conditional KO mice (CD45.2) and mixed with WT competitor marrow (CD45.1 x CD45.2) in a 1:1 ratio, which was then transplanted into lethally-irradiated primary recipient mice (CD45.1). …”

Targeted point mutation (F639A) in the GluN1 subunit decreases ethanol sensitivity of NMDA receptors. by Carolina R. den Hartog (484817)

(<i>S</i>)-PZQ decrease tone of contracted mesenteric arteries. by Gihan S. Gunaratne (5117795)

Decreased motor coordination deficits in <i>Cln6^nclf</i> mice. by Jeremy P. Morgan (479017)

PDK1 inhibitor PF-5177624 decreased IGF-I induced AKT and p70S6K phosphorylation. by Sangita M. Baxi (123560)

mGluR5 receptor decreased glycinergic currents. by Zi-Yang Zhang (4988555)

“…(<b>F</b>) Postsynaptic loading of U-0126 or PD98059 prevented CHPG from decreasing glycinergic responses (U-0126, 107.6 ± 10.4% of baseline at 15–20 min post-CHPG, <i>t</i>[8] = 0.997, <i>p</i> = 0.348; PD98059, 93.1 ± 5.0% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 0.883, <i>p</i> = 0.418). …”

The decrease in blood flow disrupts CV pruning. by Lin Wen (557398)

Blockade of mTORC2 decreased TRPC6-dependent calcium influx in podocytes (confocal microscopy). by Fangrui Ding (659863)

“…<p>(A) The podocytes were imaged at 0 seconds before the addition of hyperforin, a specific agonist of TRPC6, to record the baseline fluorescence. …”

Decrease in number of activated macrophages in demyelinated nerves subjected to 1hr ES. by Nikki A. McLean (643606)

“…Note: ES results in a significant decrease in the ED-1 IF 10d post-LPC (5d post-ES; K) and 12d post-LPC (7d post-ES; N) relative to LPC only in a pattern suggestive of movement toward lateral edges and egress (arrow). …”

HvPIN1a localisation is influenced by BFA and its expression is decreased by cytokinin. by Gwendolyn K. Kirschner (5142644)

Loss of C9orf72 decreases mTOR activation. by Janet Ugolino (3359054)

Subjects:

Stroma decreases spheroid size by decreasing cell width. by Karen F. Chambers (224337)

Cell growth and viability decrease confirmed by growth inhibition in HepG3. by Arlet Hernandez (12289155)

Juvenile demyelination leads to a decrease in axonal complexity of PFC PV interneurons. by Sara Hijazi (21656615)

“…Right</i>. The number of branch points in PV interneuron axons from cuprizone-treated mice was significantly decreased compared to control mice (<i>t test; n = 10/9 cells per group, *p < 0.05</i>). …”

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”